There is a particular kind of exhaustion that comes from being a treatment-resistant patient. It is not the exhaustion of the depression itself, although that is real. It is the exhaustion of trying medication after medication, of waiting six to eight weeks each time to see whether the latest one works, of titrating doses up and then back down, of explaining to yet another prescriber why the last three things you tried did not help. By the time someone arrives at the door of a specialist clinic, they have usually been on this carousel for years.
This piece is for patients in that position, and for the family members and clinicians supporting them. It explains what happens when the standard treatment toolkit runs out, what alternative pathways look like in 2026, and how to think about the decision to move beyond conventional medication.
Defining Treatment-Resistant Depression
There is no perfectly clean definition of treatment-resistant depression, but the working version most psychiatrists use involves a meaningful trial of at least two antidepressants from different classes, at adequate doses, for adequate durations, without sufficient improvement. Roughly a third of patients with major depressive disorder fall into this category. That is a substantial group, and historically, the options for them have been limited.
Per NIMH – Depression, what changed over the past decade is that the limitation has eased. Several treatment pathways now exist that work through mechanisms entirely different from the serotonin-focused approach of standard antidepressants. None of them are silver bullets. All of them open doors that were previously closed.
Where Standard Antidepressants Hit Their Ceiling
Selective serotonin reuptake inhibitors and their close relatives work by adjusting the availability of serotonin in the synapse. For people whose depression is downstream of serotonin signalling problems, this works well. For people whose depression has different neurobiological roots, including problems with glutamate signalling or with cortical circuit function, modifying serotonin availability is hitting the wrong target.
That mismatch explains a lot of the experience patients describe with multiple medication trials. The drugs are not failing because the patient is doing something wrong. They are failing because the underlying biology is not the kind these particular drugs are designed to address. Recognising this is the first step in moving past the mental loop of trying yet another drug from the same family and hoping for a different result.
The Two Major Alternative Pathways
Two pathways have moved from research into mainstream specialist care. The first is transcranial magnetic stimulation, which uses targeted magnetic pulses to stimulate areas of the prefrontal cortex involved in mood regulation. The second is medical ketamine, which works on glutamate pathways rather than monoamine pathways. Both have substantial evidence bases for treatment-resistant depression, and both are widely available at specialist clinics.
They differ in important ways. TMS is non-pharmacological, which appeals to patients who have struggled with medication side effects or who simply prefer not to add another long-term medication. It involves a structured course of outpatient sessions, typically five days a week for several weeks. There is no anaesthesia, no recovery time after each session, and patients drive themselves home.
Ketamine, by contrast, works fast. Many patients notice mood changes within hours or days, compared to the weeks-long timeline of antidepressants. The trade-off is that it requires a different kind of clinical setting, with monitoring during and after each treatment, and an induction-then-maintenance schedule that needs ongoing planning.
Choosing Between Pathways
There is no universally correct answer about which pathway to try first. The decision depends on the patient’s specific clinical picture, their tolerance for different kinds of treatment burden, their schedule, and what their insurance will cover. A specialist clinician should walk through these factors openly. The right starting point for a patient with severe acute symptoms who needs faster relief is not necessarily the right starting point for someone who has been at a chronic moderate level for years and can tolerate a longer build-up.
Patients searching for TMS providers in NYC should be looking for clinics that offer both TMS and ketamine and can have an honest conversation about which suits the case. Single-modality clinics will tend to recommend their modality regardless of fit.
Combination and Sequencing Strategies
Increasingly, specialists are thinking about these treatments not as alternatives but as components of a sequence or combination. A patient who responds partially to ketamine might consolidate gains with a TMS course. A patient who does well on TMS but starts to slip might benefit from periodic ketamine maintenance. Some patients respond to one quickly, then transition to the other for ongoing care.
This kind of strategic thinking requires a clinic that has experience with both modalities and can manage transitions. It is one of the reasons combined-modality clinics have become the model that most experts recommend for treatment-resistant cases. The team behind Village TMS approaches treatment planning with this combinational mindset, rather than treating each modality in isolation.
Side Effects and What to Expect
Both TMS and ketamine have side effect profiles that patients should understand before starting. TMS is generally well tolerated. The most common side effects are mild scalp discomfort during sessions and occasional headaches afterward. The risk of seizure is genuinely rare but real, and patients with certain neurological conditions or with metal in or near the head are not candidates.
Ketamine carries different considerations. The dissociative experience during treatment is often described as unusual but not unpleasant in a clinical setting, and it is monitored throughout. Blood pressure can rise during treatment and is checked. Some patients experience nausea. The longer-term safety question is well-studied for medical use, and the protocols used at responsible clinics are designed to keep patients within evidence-based ranges.
The Realities of Adherence
One of the most common reasons specialist treatment fails is not the treatment itself but the difficulty of completing the protocol. TMS courses involve a substantial schedule commitment. Ketamine courses are less dense but require multiple visits over weeks or months. Patients juggling demanding jobs or unpredictable home situations need to be honest with themselves about whether they can sustain the schedule before they start. A truncated course of either treatment is rarely as effective as a complete one.
Clinicians have a role here too. The best ones build flexibility into protocols where possible, communicate clearly about the consequences of missed sessions, and help patients problem-solve rather than simply documenting non-adherence and moving on.
Beyond the Two Major Pathways
TMS and ketamine are the most widely available alternative pathways, but they are not the only ones. For patients who have tried both without sufficient response, several other options exist. Vagus nerve stimulation has FDA approval for treatment-resistant depression. Electroconvulsive therapy remains highly effective for severe cases despite its difficult cultural reputation. Various combination strategies and adjunctive medications are available for patients who respond partially.
The point is not that any of these are guaranteed. The point is that running out of standard antidepressant options does not mean running out of options. Patients who feel they have exhausted what their general psychiatrist can offer should not assume that nothing else exists. The specialist landscape is broader than it has ever been.
